$ONCBeOne Medicines Ltd.

📅 Upcoming

🕒 Recent(90d)

News

• DPHARM: How to address the clinical trial enrollment crisis?
  Clinical trials are facing an enrollment crisis. Around 80% of trials don’t meet their enrollment timelines, and fewer than 5% of eligible adult cancer patients participate in trials.
  fiercebiotech · 14d ago
• Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'
  With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial strategies to stay ahead of the fast-moving policy environment, according…
  biospace · 21d ago
• Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
  Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbrea…
  biospace · 29d ago
• Mid-cap biotechs join Trump’s latest round of drug pricing deals
  Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
  biopharma_dive · 1mo ago
• 9 midsize drugmakers climb aboard Trump’s MFN train
  Astellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program…
  biospace · 1mo ago
• Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
  Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the growing pool of patients who progress after treatment with the modality. Th…
  fiercebiotech · 1mo ago
• Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
  Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.
  biospace · 1mo ago
• New Jazz cancer drug approval could drive blockbuster sales
  Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
  biopharma_dive · 1mo ago
• Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
  Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.
  fiercebiotech · 1mo ago
• Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
  Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
  biospace · 2mo ago